ALZCUR — AlzeCure Pharma AB Share Price
0.000.00%
Last trade - 00:00- SEK153.66m
- SEK109.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.9 | ||
| Price to Tang. Book | 3.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.38% | ||
| Return on Equity | -89.05% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | 48 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimer’s disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (Aβ) protein in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.
Directors
- Thomas Pollare CHM (65)
- Martin Jonsson CEO
- Birgitta Lundvik CFO (55)
- Johan Sandin CSO (50)
- Pontus Forsell OTH
- Magnus Halldin OTH
- Johan Lundkvist OTH
- Gunnar Nordvall OTH
- Matthias Rother OTH
- Annigje Van Es-johansson OTH (61)
- Ellen Donnelly IND (44)
- Ragnar Linder IND (66)
- Pirkko Sulila Tamsen IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 29th, 2016
- Public Since
- November 28th, 2018
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 85,129,473
- Address
- Halsovagen 7, HUDDINGE, 141 57
- Web
- https://www.alzecurepharma.se/
- Phone
- Contact
- Mikael Widell
- Auditors
- Grant Thornton Sweden AB
Upcoming Events for ALZCUR
Q4 2024 AlzeCure Pharma AB Earnings Release
Similar to ALZCUR
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
FAQ
What is the AlzeCure Pharma AB share price?
As of Today at 19:13 UTC, shares in AlzeCure Pharma AB are trading at SEK1.81. This share price information is delayed by 15 minutes.
How has the AlzeCure Pharma AB share price performed this year?
Shares in AlzeCure Pharma AB last closed at SEK1.81 and the price had moved by -47.85% over the past 365 days. In terms of relative price strength the AlzeCure Pharma AB share price has underperformed the FTSE Global All Cap Index by -54.98% over the past year.
What are the analyst and broker recommendations for AlzeCure Pharma AB?
The overall consensus recommendation for AlzeCure Pharma AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AlzeCure Pharma AB dividend yield?
AlzeCure Pharma AB does not currently pay a dividend.
Does AlzeCure Pharma AB pay a dividend?
AlzeCure Pharma AB does not currently pay a dividend.
When does AlzeCure Pharma AB next pay dividends?
AlzeCure Pharma AB does not currently pay a dividend.
How do I buy AlzeCure Pharma AB shares?
To buy shares in AlzeCure Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AlzeCure Pharma AB?
As of the previous close price of SEK1.81, shares in AlzeCure Pharma AB had a market capitalisation of SEK153.66m.
Where are AlzeCure Pharma AB shares listed?
Here are the trading details for AlzeCure Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ALZCUR
What kind of share is AlzeCure Pharma AB?
Based on an overall assessment of its quality, value and momentum AlzeCure Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AlzeCure Pharma AB share price forecast for 2024?
The analyst consensus target price for shares in AlzeCure Pharma AB is SEK8.75. That is 384.76% above the last closing price of SEK1.81.
Analysts covering AlzeCure Pharma AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.46 for the next financial year.
Find out moreWhat is the trend in the AlzeCure Pharma AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AlzeCure Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -9.5%.
As of the last closing price of SEK1.81, shares in AlzeCure Pharma AB were trading -17.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AlzeCure Pharma AB PE Ratio?
The AlzeCure Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK1.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AlzeCure Pharma AB?
AlzeCure Pharma AB's management team is headed by:
- Thomas Pollare - CHM
- Martin Jonsson - CEO
- Birgitta Lundvik - CFO
- Johan Sandin - CSO
- Pontus Forsell - OTH
- Magnus Halldin - OTH
- Johan Lundkvist - OTH
- Gunnar Nordvall - OTH
- Matthias Rother - OTH
- Annigje Van Es-johansson - OTH
- Ellen Donnelly - IND
- Ragnar Linder - IND
- Pirkko Sulila Tamsen - IND